Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age
Thng, Dexter Kai Hao Toh, Tan Boon Chow, Edward Kai-Hua
Thng, Dexter Kai Hao
Citations
Altmetric:
Alternative Title
Abstract
Deregulation of MYC is among the most frequent oncogenic drivers of cancer. Developing targeted therapies against MYC is, therefore, one of the most critical unmet needs of cancer therapy. Unfortunately, MYC has been labelled as undruggable due to the lack of success in developing clinically relevant MYC-targeted therapies. Synthetic lethality is a promising approach that targets MYC-dependent vulnerabilities in cancer. However, translating the synthetic lethality targets to the clinics is still challenging due to the complex nature of cancers. This review highlights the most promising mechanisms of MYC synthetic lethality and how these discoveries are currently translated into the clinic. Finally, we discuss how in silico computational platforms can improve clinical success of synthetic lethality-based therapy. © 2020 The Author(s)
Keywords
cancer, computational, drug targets, MYC, synthetic lethality
Source Title
Trends in Pharmacological Sciences
Publisher
Elsevier Ltd
Series/Report No.
Collections
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
Date
2021-03-01
DOI
10.1016/j.tips.2020.11.014
Type
Review